Cagrilintide + Semaglutide (CagriSema): The Amylin-GLP-1 Combo Explained
The next frontier in metabolic peptide research isn't a single molecule — it's a combination. CagriSema, a fixed-ratio co-formulation of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, has emerged from Novo Nordisk's pipeline as one of the most closely watched investigational therapies in obesity and type 2 diabetes research. Early clinical data suggest the combination produces weight loss effects that exceed either agent alone, pointing to a powerful synergy between two distinct gut-brain signaling pathways.
Why Combine Amylin and GLP-1?
Amylin and GLP-1 are both peptide hormones co-secreted with insulin after meals, but they act through different receptors and complementary mechanisms. GLP-1 receptor agonists like semaglutide enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic and brainstem circuits. Amylin, co-secreted by pancreatic beta cells, independently slows gastric emptying, suppresses post-meal glucagon, and promotes satiety through the area postrema and other hindbrain regions.
The rationale for combining them is straightforward: activating both pathways simultaneously may produce additive or even synergistic reductions in appetite and caloric intake. Preclinical work in rodent models demonstrated that dual amylin-GLP-1 agonism produced greater weight loss than either pathway alone, with distinct neuronal activation patterns in the brainstem suggesting non-overlapping mechanisms of action (Liberini et al., 2019).
What Is Cagrilintide?
Cagrilintide (previously NN9838) is a long-acting acylated amylin analog engineered for once-weekly subcutaneous administration. Native human amylin (also called islet amyloid polypeptide, or IAPP) has a half-life of only about 15 minutes, making it impractical for sustained therapy. Pramlintide, the only approved amylin analog, requires multiple daily injections.
Cagrilintide solves this problem through fatty acid acylation and strategic amino acid substitutions that extend its half-life to approximately 160 hours, enabling weekly dosing. It binds to the calcitonin receptor (CTR) and AMY receptor subtypes (AMY1 and AMY3), the same receptor complexes activated by native amylin (Lau et al., 2021).
As a standalone agent, cagrilintide showed meaningful weight loss in the Phase 2 trial published by Enebo et al., 202100845-X). In that 26-week study, participants with overweight or obesity receiving the highest dose of cagrilintide (4.5 mg weekly) achieved 10.8% mean body weight loss compared to 3.0% with placebo — a notable result for an amylin analog alone.
Semaglutide: The Established GLP-1 Backbone
Semaglutide needs less introduction. Originally developed for type 2 diabetes (Ozempic®) and later approved for chronic weight management at 2.4 mg weekly (Wegovy®), semaglutide is a GLP-1 receptor agonist with a half-life of approximately one week. Its efficacy in obesity was firmly established in the STEP trial program.
In the landmark STEP 1 trial, semaglutide 2.4 mg produced 14.9% mean body weight loss over 68 weeks versus 2.4% for placebo (Wilding et al., 2021). These results set a high bar for any combination approach to demonstrate meaningful additional benefit.
Phase 2 Data: The Combination Outperforms Monotherapy
The pivotal Phase 2 evidence for CagriSema came from a 32-week randomized, double-blind trial in adults with overweight or obesity, published by Frias et al., 202301084-X). This study directly compared three arms:
The results were striking. At 32 weeks, the mean body weight change was:
Notably, the semaglutide monotherapy arm showed lower-than-expected weight loss, likely because the 32-week duration didn't allow full dose escalation to reach steady-state efficacy. However, the combination arm's 15.6% loss at just 32 weeks — a timepoint where semaglutide monotherapy is typically still climbing — suggested a genuinely accelerated trajectory of weight reduction.
Phase 3 REDEFINE Program: What We Know So Far
Novo Nordisk launched the REDEFINE Phase 3 clinical trial program to evaluate CagriSema across multiple populations, including adults with obesity, type 2 diabetes, and obesity-related comorbidities. The program comprises several trials registered on ClinicalTrials.gov, including REDEFINE 1 (NCT05567796) and REDEFINE 2 (NCT05394519).
Results from REDEFINE 1, the 68-week pivotal obesity trial, were reported in early 2025. CagriSema achieved a mean body weight reduction of 22.7% from baseline, compared with 15.6% for semaglutide 2.4 mg alone and 1.1% for placebo (Novo Nordisk Press Release, 2024). This ~7 percentage point advantage over semaglutide monotherapy represents a clinically meaningful increment.
REDEFINE 2 focused on patients with type 2 diabetes and obesity. Top-line results showed CagriSema delivered 15.7% weight loss alongside 2.2 percentage point HbA1c reduction at 68 weeks — outperforming semaglutide alone on both endpoints (Novo Nordisk Press Release, 2024).
Safety and Tolerability Profile
The adverse event profile of CagriSema has largely mirrored what researchers expect from GLP-1 and amylin agonism. Gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — remain the most commonly reported events across trials. In the Phase 2 combination study, 41% of CagriSema participants reported nausea, compared with 22% for semaglutide alone (Frias et al., 202301084-X)).
Treatment discontinuation rates due to adverse events have generally been modest but slightly higher in the combination arm. The gradual dose-escalation protocol used in CagriSema trials is specifically designed to mitigate GI tolerability issues.
There are theoretical concerns worth monitoring in longer-term studies. Amylin analogs at high concentrations can promote amyloid fibril formation, though cagrilintide's molecular design incorporates substitutions intended to reduce aggregation propensity. Cardiovascular outcomes data for the combination are not yet available, though semaglutide's standalone cardiovascular benefit is well-documented from the SELECT trial (Lincoff et al., 2023).
Mechanism of Synergy: What the Science Suggests
The precise mechanism behind the additive weight loss remains an active area of investigation. Research using functional neuroimaging and rodent models suggests that amylin and GLP-1 activate partially distinct neuronal populations in the brainstem and hypothalamus.
GLP-1 receptors are densely expressed in the nucleus tractus solitarius (NTS) and hypothalamic arcuate nucleus, while amylin signals primarily through the area postrema and lateral parabrachial nucleus. A study by Reiner et al., 2017 demonstrated that amylin receptor signaling in the ventral tegmental area can reduce motivation-driven feeding — a pathway distinct from GLP-1's primary mechanisms.
This neuroanatomical separation likely explains why combining both peptides produces greater appetite suppression than maximizing either pathway alone. It also raises the possibility that the combination could be effective in individuals who show incomplete responses to GLP-1 monotherapy.
Competitive Landscape and Future Directions
CagriSema enters a rapidly crowding field. Tirzepatide (Mounjaro®/Zepbound®), a dual GIP/GLP-1 agonist, demonstrated up to 22.5% weight loss in the SURMOUNT-1 trial (Jastreboff et al., 2022). Survodutide, retatrutide, and other multi-agonists are also advancing through clinical development.
CagriSema's mechanism is fundamentally different from these approaches — rather than combining incretin pathways, it pairs an incretin with a non-incretin pancreatic hormone. Whether this translates to advantages in specific subpopulations, body composition effects, or long-term weight maintenance remains to be determined.